-DOCSTART- -X- O
We -X- _ O
have -X- _ O
previously -X- _ O
described -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
a -X- _ O
double -X- _ O
coated -X- _ O
agarose-agarose -X- _ O
porcine -X- _ O
islet -X- _ O
macrobead -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
type -X- _ O
I -X- _ O
diabetes -X- _ O
mellitus. -X- _ O
In -X- _ O
the -X- _ O
current -X- _ O
study -X- _ O
, -X- _ O
the -X- _ O
long-term -X- _ O
viral -X- _ O
safety -X- _ O
of -X- _ O
macrobead -X- _ B-Intervention
implantation -X- _ I-Intervention
into -X- _ O
pancreatectomized -X- _ B-Patient
diabetic -X- _ I-Patient
dogs -X- _ I-Patient
treated -X- _ I-Patient
with -X- _ I-Patient
pravastatin -X- _ I-Patient
( -X- _ I-Patient
n -X- _ I-Patient
= -X- _ I-Patient
3 -X- _ I-Patient
) -X- _ I-Patient
was -X- _ O
assessed -X- _ O
while -X- _ O
2 -X- _ B-Comparison
dogs -X- _ I-Comparison
served -X- _ I-Comparison
as -X- _ I-Comparison
nonimplanted -X- _ I-Comparison
controls. -X- _ I-Comparison
A -X- _ B-Outcome
more -X- _ I-Outcome
gradual -X- _ I-Outcome
return -X- _ I-Outcome
to -X- _ I-Outcome
preimplant -X- _ I-Outcome
insulin -X- _ I-Outcome
requirements -X- _ I-Outcome
occurred -X- _ I-Outcome
after -X- _ I-Outcome
a -X- _ I-Outcome
2nd -X- _ I-Outcome
implant -X- _ I-Outcome
procedure -X- _ I-Outcome
( -X- _ I-Outcome
days -X- _ I-Outcome
148 -X- _ I-Outcome
, -X- _ I-Outcome
189 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
> -X- _ I-Outcome
652 -X- _ I-Outcome
) -X- _ I-Outcome
when -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
first -X- _ I-Outcome
macrobead -X- _ I-Outcome
implantation -X- _ I-Outcome
( -X- _ I-Outcome
days -X- _ I-Outcome
9 -X- _ I-Outcome
, -X- _ I-Outcome
21 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
21 -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
macrobead -X- _ I-Outcome
implanted -X- _ I-Outcome
animals. -X- _ I-Outcome
In -X- _ I-Outcome
all -X- _ I-Outcome
three -X- _ I-Outcome
implanted -X- _ I-Outcome
dogs -X- _ I-Outcome
, -X- _ I-Outcome
porcine -X- _ I-Outcome
C-peptide -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
blood -X- _ I-Outcome
for -X- _ I-Outcome
at -X- _ I-Outcome
least -X- _ I-Outcome
10 -X- _ I-Outcome
days -X- _ I-Outcome
following -X- _ I-Outcome
the -X- _ I-Outcome
first -X- _ I-Outcome
implant -X- _ I-Outcome
and -X- _ I-Outcome
for -X- _ I-Outcome
at -X- _ I-Outcome
least -X- _ I-Outcome
26 -X- _ I-Outcome
days -X- _ I-Outcome
following -X- _ I-Outcome
the -X- _ I-Outcome
second -X- _ I-Outcome
implant. -X- _ I-Outcome
C-peptide -X- _ I-Outcome
was -X- _ I-Outcome
also -X- _ I-Outcome
present -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
peritoneal -X- _ I-Outcome
fluid -X- _ I-Outcome
of -X- _ I-Outcome
all -X- _ I-Outcome
three -X- _ I-Outcome
implanted -X- _ I-Outcome
dogs -X- _ I-Outcome
at -X- _ I-Outcome
6 -X- _ I-Outcome
months -X- _ I-Outcome
after -X- _ I-Outcome
2nd -X- _ I-Outcome
implant -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
2 -X- _ I-Outcome
of -X- _ I-Outcome
3 -X- _ I-Outcome
dogs -X- _ I-Outcome
at -X- _ I-Outcome
necropsy. -X- _ I-Outcome
Prescreening -X- _ I-Outcome
results -X- _ I-Outcome
of -X- _ I-Outcome
islet -X- _ I-Outcome
macrobeads -X- _ I-Outcome
and -X- _ I-Outcome
culture -X- _ I-Outcome
media -X- _ I-Outcome
prior -X- _ I-Outcome
to -X- _ I-Outcome
transplantation -X- _ I-Outcome
were -X- _ I-Outcome
negative -X- _ I-Outcome
for -X- _ I-Outcome
13 -X- _ I-Outcome
viruses. -X- _ I-Outcome
No -X- _ I-Outcome
evidence -X- _ I-Outcome
of -X- _ I-Outcome
PERV -X- _ I-Outcome
or -X- _ I-Outcome
other -X- _ I-Outcome
viral -X- _ I-Outcome
transmission -X- _ I-Outcome
was -X- _ I-Outcome
found -X- _ I-Outcome
throughout -X- _ I-Outcome
the -X- _ I-Outcome
study. -X- _ I-Outcome
This -X- _ O
study -X- _ O
demonstrates -X- _ O
that -X- _ O
the -X- _ O
long-term -X- _ O
( -X- _ O
2.4 -X- _ O
years -X- _ O
) -X- _ O
implantation -X- _ O
of -X- _ O
agarose-agarose -X- _ O
encapsulated -X- _ O

